Potential of muvalaplin as a lipoprotein(a) inhibitor

Expert Opin Investig Drugs. 2024 Jan;33(1):5-7. doi: 10.1080/13543784.2024.2302592. Epub 2024 Feb 12.

Authors

Amanda J Hooper^{1

2}, P Mihika S Fernando¹, John R Burnett^{1

2}

Affiliations

¹ Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network, Perth, Western Australia, Australia.
² School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

PMID: 38186354
DOI: 10.1080/13543784.2024.2302592

No abstract available

Keywords: ApoB; LDL; LDL-cholesterol; Lp(a); Lp(a) inhibitor; muvalaplin.

Publication types

Editorial

MeSH terms

Cholesterol, LDL
Humans
Lipoprotein(a)*

Substances

Lipoprotein(a)
Cholesterol, LDL